Tapimmune Inc (NASDAQ:TPIV) Shorted Shares Rose By 18.44%

June 27, 2018 - By Matthew Medley

TapImmune, Inc. (NASDAQ:TPIV) Corporate Logo

Change of 18.44% for Tapimmune Inc (NASDAQ:TPIV)’s shares shorted was reported. FINRA published shares shorted of TPIV’s total 37,900 shares. The 32,000 previous shares are up with 18.44%. Tapimmune Inc (NASDAQ:TPIV) has 43,500 shares average volume. It’ll cost 1 days for TPIV to recover its previous position. Tapimmune Inc float short is 0.38%.

Ticker’s shares touched $10.74 during the last trading session after 2.29% change.Currently TapImmune, Inc. is uptrending after 4.55% change in last June 27, 2017. TPIV has 442,085 shares volume. TPIV underperformed by 8.02% the S&P 500.

TapImmune, Inc., a clinical-stage immuno-oncology company, develops peptide and gene immunotherapeutics and vaccines for the treatment of cancer and metastatic disease.The company has $137.12 million market cap. It specializes in the development of immunotherapies targeting women??s cancers advancing multiple Phase II and Phase Ib/II clinical studies for the treatment of ovarian and breast cancers.Last it reported negative earnings. The company??s peptide-or nucleic acid immunotherapeutic products comprise one or multiple naturally processed epitopes designed to comprehensively stimulate a patient??s killer T cells and helper T cells, and to restore or further augment antigen presentation by using proprietary nucleic acid expression systems.

More recent TapImmune, Inc. (NASDAQ:TPIV) news were posted by Seekingalpha.com, Benzinga.com and Nasdaq.com. The first one has “The Kite Killer – TapImmune And Marker Merger Challenges Gilead” as a title and was posted on May 30, 2018. The next is “TapImmune Poised To Become A Cell Therapy Leader, WBB Securities Says In Upgrade” on June 03, 2018. And last was posted on June 11, 2018, called “Mid-Afternoon Market Update: Dow Rises 80 Points; Nano Dimension Shares Spike Higher”.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.